Pemphigus encompasses a heterogeneous group of autoimmune blistering diseases, which
affect both mucous membranes and the skin. The disease usually runs a chronic-relapsing …

Rituximab is a B cell depleting monoclonal antibody that targets the B cell-specific cell
surface antigen CD20 and is currently used to treat several autoimmune diseases. The …

Abstract Rituximab (MabThera®, Rituxan®), a chimeric murine/human anti-CD20
monoclonal antibody administered by intravenous infusion, is indicated for the treatment of …

The place of pemphigus vulgaris (PV) among autoimmune bullous dermatoses is well
known. In pemphigus, IgG autoantibodies are directed against desmogleins 1 and 3, which …

Desquamative gingivitis (DG) is a clinical term that describes erythema, desquamation and
erosions of the gingiva, of various etiologies. Although the clinical aspect is not specific for a …

Pemphigus is a severe autoimmune bullous dermatosis that affects the skin and/or mucosa,
and it may be life-threatening without proper treatment. The guidelines and/or consensus …

Pemphigus is a rare autoimmune blistering disease, involving potentially life-threatening
conditions often requiring immunosuppression. Currently, the COVID-19 pandemic caused …

The aim of the treatment in autoimmune blistering diseases (AIBDs) is to induce and
maintain remission, which clinically corresponds to the cessation of new vesicle formation …

Pemphigus is a chronic and severe autoimmune bullous disease caused by autoantibodies
targeting adhesion molecules between keratinocytes. It requires 2–3 years on average to …

Pemphigus vulgaris is a chronic autoimmune mucocutaneous blistering disorder. Apart from
the disease itself, other aspects of patients' life, including psychological, social, and …